Гормональный профиль и клинические проявления дефицита андрогенов у женщин в период менопаузы и актуальные аспекты, связанные с назначением гормональной терапии


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Андрогены играют одну из ключевых ролей в физиопатологии женщин. Возрастное снижение синтеза андрогенов яичникового и надпочечникового происхождения может существенно влиять на здоровье женщин. Снижение уровня андрогенов является результатом пониженной функции яичников и связанного с возрастом снижения синтеза андрогенов надпочечниками. Относительный дефицит андрогенов у женщин в пре- и постменопаузе может вызывать ухудшение сексуальной функции, либидо, психоэмоционального здоровья и снижение когнитивных функций, а также влияет на сердечно-сосудистую и костно-мышечную системы. Возможности лечения сниженного полового влечения многогранны и должны включать в себя как менопаузальную гормонотерапию, так и индивидуальную психосоциальную терапию.

Полный текст

Доступ закрыт

Об авторах

Марина Антоновна Шевцова

ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России

Email: marina_981995@mail.ru
ординатор

Линда Таймуразовна Цховребова

ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России

Email: linda.tskhovrebova@mail.ru
ординатор

Алла Анатольевна Гависова

ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России

Email: gavialla@yandex.ru
к.м.н., старший научный сотрудник 1-го гинекологического отделения

Список литературы

  1. Labrie F, Martel C, Belanger A., Pelletier G. Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology. J. Steroid Biochem. Mol. Biol. 2017; 168: 9-18. https://dx.doi.org/10.1016/j. jsbmb.2016.12.007.
  2. Schifer L., Kempegowda P., Arlt W., O’Reilly M.W. Mechanisms in endocrinology: the sexually dimorphic role of androgens in human metabolic disease. Eur. J. Endocrinol. 2o17; 177(3): R125-43. https://dx.doi.org/10.1530/eje-17-0124.
  3. Soman M., Huang L.C., Cai W.H., Xu J.B., Chen J.Y., He R.K. et al. Serum androgen profles in women with premature ovarian insufciency: a systematic re-view and meta-analysis. Menopause. 2019; 26(1): 78-93. https://dx.doi. org/10.1097/gme.0000000000001161.
  4. Miller K.K., Biller B.M.K., Beauregard C., Lipman J.G., Jones J., Schoenfeld D. et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2006; 91(5): 1683-90.
  5. Hovi L., Saarinen-Pihkala U.M., Taskinen M., Wilkstrom A.M., Dunkel L. Subnormal androgen levels in young female bone marrow transplant with ovarian disfunction, chronic GVHD and receiving glucocorticoid therapy. Bone Marrow Transplant. 2004; 33(5): 503-8.
  6. Pluchino N., Carmignani A., Cubeddu A., Santoro A., Cela V., Errasti T. Androgen therapy in women: for whom and when. Arch. Gynecol. Obstet. 2013; 288(4): 731-7. https://dx.doi.org/10.1007/s0040 4-013-2969-7.
  7. Traish A.M., Vignozzi L., Simon J.A., Goldstein I., Kim N.N. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex. Med. Rev. 2018; 6(4): 558-71. https://doi. org/10.1016/j. sxmr.2018.03.005.
  8. Wierman M.E., Basson R., Davis S.R., Khosla S., Miller K.K., Rosner W., Santoro N. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab. 2006 Oct; 91(10):3697-710. https://doi. org/10.1210/jc.2006-1121.
  9. Pancer C., Guay A. Testosterone replacement therapy in naturally and surgically menopausal women. J. Sex. Med. 2009; 6: 8-18.
  10. Davis S.R., Davison S.L., Donath S., Bell R.J. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005; 294(1): 91-6.
  11. Randolph J.F. Jr., Zheng H., Avis N.E., Greendale G.A., Harlow S.D. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J. Clin. Endocrinol. Metab. 2015; 100(1): 258-66. https://dx.doi.org/10.1210/jc.2014-1725.
  12. Rosen R., Brown C., Heiman J., Leiblum S., Meston C., Shabsigh R. et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2): 191-208. https://dx.doi.org/10.1080/009262300278597.
  13. Wahlin-Jacobsen S., Pedersen A.T., Kristensen E., Laessoe N.C., Lundqvist M., Cohen A.S. et al. Is there a correlation between androgens and sexual desire in women? J. Sex. Med. 2015; 12(2): 358-73. https://dx.doi.org/10.1111/ jsm.12774.
  14. Wierman M.E., Arlt W., Basson R., Davis S.R., Miller K.K., Murad M.H. et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2014; 99(10): 3489-510. https:// dx.doi.org/10.1210/jc.2014-2260.
  15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Press; 1994.
  16. Elraiyah T., Sonbol M.B., Wang Z., Khairalseed T., Asi N., Undavalli C. et al. Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2014; 99(10): 3543-50. https:// dx.doi.org/10.1210/jc.2014-2262.
  17. Somboonporn W., Davis S., Seif M.W., Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst. Rev. 2005; (4): CD004509.
  18. Islam R.M., Bell R.J., Green S., Page M.J., Davis S.R. Safety and efcacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019; 7(10): 754-66. https:// dx.doi.org/10.1016/s2213 -8587(19)30189-5.
  19. Davis S.R., Baber R., Panay N., Bitzer J., Perez S.C., Islam R.M. et al. Global consensus position statement on the use of testosterone therapy for women. J. Clin. Endocrinol. Metab. 2019; 104(10): 4660-6. https://dx.doi.org/10.1210/ jc.2019-01603.
  20. Prough R.A., Clark B.J., Klinge C.M. Novel mechanisms for DHEA action. J. Mol. Endocrinol. 2016; 56(3): R139-55. https://dx.doi. org/10.1530/jme-16- 0013.
  21. Li H., Sun J., Xu Z. Biotransformation of DHEA into 7alpha,15alpha-diOH-DHEA. Methods Mol. Biol. (Clifton, NJ) 2017; 1645: 289-95. https://dx.doi. org/10.1007/978-1-4939-7183-1_20.
  22. Marsden J. British Menopause Society consensus statement: the risks and benefits of HRT before and after a breast cancer diagnosis. Post Reprod. Health. 2019; 25(1): 33-7. https://dx.doi. org/10.1177/2053369119825716.
  23. Davis S.R. Cardiovascular and cancer safety of testosterone in women. Curr. Opin. Endocrinol. Diabetes Obes. 2011; 18(3): 198-203. https://dx.doi. org/10.1097/MED.0b013e328344f449.
  24. Somboonporn W., Davis S.R. Testosterone efects on the breast: implications for testosterone therapy for women. Endocr. Rev. 2004; 25(3): 374-88. https:// dx.doi.org/10.1210/er.2003-0016.
  25. Misso M.L., Jang C., Adams J., Tran J., Murata Y., Bell R. et al. Adipose aromatase gene expression is greater in older women and is unafected by postmenopausal estrogen therapy. Menopause. 2005; 12(2): 210-5
  26. Labrie F, Luu-The V., Labrie C., Belanger A., Simard J., Lin S.X., Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 2003; 24(2): 152-82. https://dx.doi.org/10.1210/er.2001-0031.
  27. Gera R., Tayeh S., Chehade H.E., Mokbel K. Does transdermal testosterone increase the risk of developing breast cancer? A systematic review. Anticancer Res. 2018; 38(12): 6615-20. https://dx.doi. org/10.21873/anticanres.13028.
  28. Braunstein G.D., Sundwall D.A., Katz M., Shifren J.L., Buster J.E., Simon J.A. et al. Safety and efcacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch. Intern. Med. 2005; 165(14): 1582-9. https://dx.doi. org/10.1001/archinte.165.14.1582.
  29. Buster J.E., Kingsberg S.A., Aguirre O., Brown C., Breaux J.G., Buch A. et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet. Gynecol. 2005; 105(5, Pt 1): 944-52. https:// dx.doi. org/10.1097/01.AOG.0000158103.27672.0d.
  30. Wallace I.R., McKinley M.C., Bell P.M., Hunter S.J. Sex hormone binding globulin and insulin resistance. Clin. Endocrinol. 2013; 78(3): 321-9. https:// dx.doi.org/10.1111/cen.12086.
  31. Ding E.L., Song Y., Manson J.E., Hunter D.J., Lee C.C., Rifai N. et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N. Engl. J. Med. 2009; 361(12): 1152-63. https://dx.doi.org/10.1056/ NEJMoa0804381.
  32. Worsley R., Robinson P.J., Bell R.J., Moufarege A., Davis S.R. Endogenous estrogen and androgen levels are not independent predictors of lipid levels in postmenopausal women. Menopause. 2013; 20(6): 640-5. https://dx.doi. org/10.1097/GME.0b013e318279bd4a.
  33. Labrie F, Derogatis L., Archer D.F., Koltun W., Vachon A., Young D. et al. Efect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J. Sex. Med. 2015; 12(12): 2401-12. https://dx.doi. org/10.1111/jsm.13045.
  34. Davis S.R., Worsley R., Miller K.K., Parish S.J., Santoro N. Androgens and female sexual function and dysfunction-fndings from the fourth international consultation of sexual medicine. J. Sex. Med. 2016; 13(2): 168-78. https:// dx.doi.org/10.1016/j. jsxm.2015.12.033.
  35. Arlt W., Callies F., Koehler I., van Vlijmen J.C., Fassnacht M., Strasburger C.J. et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J. Clin. Endocrinol. Metab. 2001; 86(10): 4686-92. https://doi.org/10.1210/jcem.86.10.7974.
  36. Davis S.R., Shah S.M., McKenzie D.P., Kulkarni J., Davison S.L., Bell R.J. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J. Clin. Endocrinol. Metab. 2008; 93(3): 801-8. https:// dx.doi.org/10.1210/ jc.2007-2128.
  37. Rosario E.R., Chang L., Head E.H., Stanczyk F.Z., Pike C.J. Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer’s disease. Neurobiol. Agin.g 2011; 32(4): 604-13. https://dx.doi.org/10.1016/j. neurobiolaging.2009.04.008.
  38. Brown C.M., Mulcahey T.A., Filipek N.C., Wise P.M. Production of proin-flammatory cytokines and chemokines during neuroinflammation: novel roles for estrogen receptors alpha and beta. Endocrinology. 2010; 151(10): 4916-25. https://dx.doi.org/10.1210/en.2010-0371.
  39. Drake E.B., Henderson V.W., Stanczyk F.Z., McCleary C.A., Brown W.S., Smith C.A. et al. Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology. 2000; 543: 599-603. https:// dx.doi.org/10.1212/wnl.54.3.599.
  40. Aleman A., Bronk E., Kessels R.P., Koppeschaar H.P., van Honk J. A single administration of testosterone improves visuospatial ability in young women. Psychoneuroendocrinology 2004; 29(5): 612-7. 1 https://dx.doi.org/10.1016/ S0306-4530(03)00089-1.
  41. Davis S.R., Jane F., Robinson P.J., Davison S.L., Worsley R., Maruff P., Bell R.J. Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. Clin. Endocrinol. (Oxf). 2014; 81(4): 621-8. https://dx.doi.org/10.1111/cen.12459.
  42. Clarke B.L., Khosla S. Androgens and bone. Steroids. 2009; 74(3): 296-305. 10.1016/j.steroids.2008.10.003.
  43. Almeida M., Laurent M.R., Dubois V., Claessens F., O 'Brien C.A., Bouillon R., Vanderschueren D., Manolagas S.C. Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev. 2017 Jan; 97(1):135-87. https:// dx.doi.org/10.1152/physrev.00033.2015.PMID: 27807202.
  44. Barrett-Connor E., Young R., Notelovitz M., Sullivan J., Wiita B., Yang H.M. Nolan J. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J. Reprod. Med. 1999; 44(12): 1012-20.
  45. Popat V.B., Calis K.A., Kalantaridou S.N., Vanderhoof V.H., Koziol D., Troendle J.F. et al. Bone mineral density in young women with primary ovarian in-sufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J. Clin. Endocrinol. Metab. 2014; 99(9): 3418-26. https://dx.doi.org/10.1210/jc.2013-4145.
  46. Rariy C.M., Ratcliffe S.J., Weinstein R. et al. Higher serum free testosterone concentration in older women is associated with greater bone mineral density, lean body mass, and total fat mass: the cardiovascular health study. J. Clin. En-docrinol. Metab. 2011; 96: 989-96.
  47. Dobs A.S., Nguyen T., Pace C., Roberts C.P. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J. Clin. Endocrinol. Metab. 2002; 87(4): 1509-16. https://dx.doi.org/10.1210/jcem.87.4.8362.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах